

SOUTH WEST CLINICAL SENATE COUNCIL MEETING
DECEMBER 6TH 2017

To what extent and how should the transition to use of biosimilar medicines be prioritised to enable the provision of best value care in the NHS? Does the Clinical Senate support the uptake of biosimilar medicines at pace and how can their best practice use be maximised?



MSD

INVENTING FOR LIFE

The organisers of this event have not paid or sponsored our attendance or any part of the message being delivered.

Industry perspective

Disclaimer: views are those of the author but the author represents an organisation which has experience of being in a market with biosimilars (Infliximab) and is involved in the development of biosimilars.

- Metrics
 - Objective
 - Impact
 - Access
 - Outcomes
- Best Value
- Sustainability of Procurement model
- Patient engagement
- Switching

Practical considerations

- Engagement with Industry
- Competition
- Originator on Framework
- Incentives – impact
 - Improved services
- Extended stability
- Transparency of price